Stocktoria
KIORA PHARMACEUTICALS INC KPRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-02-13
KIORA PHARMACEUTICALS INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $16.0M | $0 | — | $0 |
| R&D expense | $10.8M | $7.8M | $4.0M | $3.4M | $5.4M |
| Operating income | -$12.8M | $4.5M | -$12.6M | -$12.3M | -$14.2M |
| Interest expense | — | — | $11,132 | $8,599 | $6,851 |
| Income tax | -$1.3M | $2.1M | $90,319 | -$113,010 | -$192,603 |
| Net income | -$10.8M | $3.6M | -$12.5M | -$13.6M | -$13.8M |
| EPS (diluted) | $-2.64 | $0.87 | $-24.25 | $-18.55 | $-57.12 |
| Operating cash flow | -$10.0M | $8.6M | -$9.6M | -$10.4M | -$10.7M |
| Free cash flow | -$10.1M | $8.6M | -$9.6M | -$10.4M | -$10.7M |
| Cash & equivalents | $8.7M | $3.8M | $2.5M | $6.0M | $7.9M |
| Total assets | $24.3M | $36.5M | $13.7M | $18.7M | $20.1M |
| Total liabilities | $8.1M | $10.7M | $7.6M | $7.3M | $5.6M |
| Shareholders' equity | $16.1M | $25.8M | $6.1M | $11.4M | $14.6M |
Source: SEC EDGAR filings · CIK 0001372514 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.